Investing.com reported in October 2026 that InvestingPro’s Fair Value analysis flagged Vaxcyte (NASDAQ: PCVX) as overvalued in September 2024. Its retrospective says the shares were then $111.58, against a $62.99 Fair Value estimate, implying 43.55% downside; it says the later price was $56.90, a 49.19% decline. Those figures make the story plausible, but the available evidence does not independently verify the original model or the historical prices. Investing.com’s retrospective is the source for the figures.
What Investing.com says InvestingPro forecast
In an October 1, 2026 retrospective, Investing.com said InvestingPro’s Fair Value analysis identified Vaxcyte as overvalued in September 2024. The retrospective gives a share price of $111.58 and a Fair Value estimate of $62.99. Comparing those figures implies about 43.55% downside from the then-price. It also reports a later price of $56.90 and describes the fall as 49.19%.
The rounded prices themselves imply a decline of about 49.0%, not exactly 49.19%. The more precise percentage may reflect underlying figures or a calculation detail that the retrospective does not state. The estimate’s implied downside and the subsequent reported fall are also different comparisons: one measures the gap between the September 2024 price and estimate; the other measures the later price change.
Was the prediction independently verified?
No. The figures come from Investing.com’s later account, not an archived September 2024 InvestingPro model record. The available material also does not provide an independently sourced historical price series matching the dates and price definitions. The reported match is therefore an attributed retrospective claim, not an independently verified forecast test.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →#1 Best Overall
That matters because a forecast can only be evaluated fairly when its original timestamp, assumptions, valuation date, model version, target and time horizon are known. Without the dated estimate, it is not possible to establish whether the $62.99 value was available to investors at the time, whether it was later revised, or precisely how the stated outcome period was measured.
What a fair forecast check would require
- Timestamp and archive: Find the original model output or another dated record showing the estimate as it existed in September 2024.
- Comparable prices: Confirm the starting and ending prices, dates, and whether they are closing, intraday or adjusted prices.
- Defined horizon: Identify whether the estimate was a price target for a specified date or a valuation comparison without a stated forecast period.
- Method and inputs: Review the model version, assumptions and valuation inputs rather than treating a Fair Value figure as a guaranteed price prediction.
- Documented developments: Separate company, clinical, financing and broader market events that are documented from explanations merely asserted after the stock moved.
Investing.com published a separate retrospective in 2025 about a January 2024 call: it reported a $62.94 estimate, 45.33% predicted downside, and a later $33.95 price with a 46% decline by August 2025. That is a distinct episode, not additional verification of the September 2024 claim. Investing.com’s earlier retrospective is the source for those figures.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
Company context is not proof of why the stock moved
Vaxcyte describes itself as a clinical-stage vaccine company developing vaccines for bacterial infectious diseases. Its 2025 Form 10-K said it had no products approved for commercial sale. The filing reported net losses of $766.6 million in 2025 and $463.9 million in 2024, and an accumulated deficit of $2.2 billion as of December 31, 2025. These issuer-reported facts describe the business and its financial position; they do not establish that losses caused the reported share-price decline or validate the Fair Value estimate. Vaxcyte’s 2025 Form 10-K, filed with the SEC.
In an August 5, 2026 company update, Vaxcyte reported $2.5 billion in cash, cash equivalents and investments as of June 30, 2026. The same update said 6,191 adults had been dosed across three VAX-31 Phase 3 trials, approximately 3,500 of them with VAX-31. Those figures provide company-reported operating context, not a measure of what the shares were worth. Vaxcyte’s August 5, 2026 update.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Clinical milestones were expectations, not completed results
In that August 2026 update, Vaxcyte said its three adult VAX-31 Phase 3 OPUS trials were fully enrolled. The company expected OPUS-1 topline data in the fourth quarter of 2026 and OPUS-2 and OPUS-3 results in the first half of 2027. These were plans and expectations stated by the company, not reported trial outcomes.
CEO and co-founder Grant Pickering said on August 5, 2026: “With the VAX-31 OPUS-1, OPUS-2 and OPUS-3 Phase 3 trials and the VAX-31 Phase 2 infant study fully enrolled, we expect a series of meaningful clinical study readouts across our adult and infant pneumococcal conjugate vaccines (PCV) franchise over the next 12 months,” Vaxcyte’s company update. This is an executive’s forward-looking statement, not an independent assessment of the candidate or a verified explanation of PCVX’s earlier performance.
Rank #4
Vaxcyte’s homepage describes VAX-31 as designed to increase coverage of pneumococcal disease in adults and children. That is a description of the candidate’s intended coverage, not evidence of clinical effectiveness or regulatory approval. Vaxcyte’s homepage.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What investors can conclude
The figures reported by Investing.com show that its September 2024 Fair Value estimate was below the then-price and that a later price was lower still. But one retrospective example cannot establish that InvestingPro reliably predicts stock declines, that the estimate was unchanged or available in its reported form at the time, or that the model explains what happened afterward. Those conclusions would require the original dated model record and independently matched price data, along with a defined forecast horizon.
Quick Recap
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
